Polaryx Therapeutics, Inc. Common Stock (PLYX) - Total Liabilities
Based on the latest financial reports, Polaryx Therapeutics, Inc. Common Stock (PLYX) has total liabilities worth $873.00K USD as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. See how liquid is Polaryx Therapeutics, Inc. Common Stock's working capital to evaluate short-term liquidity relative to the company's equity base.
Polaryx Therapeutics, Inc. Common Stock - Total Liabilities Trend (2023–2025)
This chart illustrates how Polaryx Therapeutics, Inc. Common Stock's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see PLYX total assets.
Polaryx Therapeutics, Inc. Common Stock Competitors by Total Liabilities
The table below lists competitors of Polaryx Therapeutics, Inc. Common Stock ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
IL Science Co. Ltd
KQ:307180
|
Korea | ₩125.87 Billion |
|
Calida Holding AG
SW:CALN
|
Switzerland | CHF43.81 Million |
|
Farcent Enterprise Co Ltd
TW:1730
|
Taiwan | NT$584.97 Million |
|
Alkim Alkali Kimya AS
IS:ALKIM
|
Turkey | TL1.41 Billion |
|
Grupo Ortiz Properties Socimi
MC:YGOP
|
Spain | €101.27 Million |
|
Zeotech Ltd
AU:ZEO
|
Australia | AU$1.12 Million |
|
ZHEJIANG SHIBAO H YC 1
F:W4K1
|
Germany | €1.65 Billion |
|
Luda Technology Group Limited
NYSE MKT:LUD
|
USA | $26.24 Million |
Liability Composition Analysis (2023–2025)
This chart breaks down Polaryx Therapeutics, Inc. Common Stock's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See Polaryx Therapeutics, Inc. Common Stock balance sheet independence to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 13.53 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.08 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.07 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Polaryx Therapeutics, Inc. Common Stock's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Polaryx Therapeutics, Inc. Common Stock (2023–2025)
The table below shows the annual total liabilities of Polaryx Therapeutics, Inc. Common Stock from 2023 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $855.00K | +195.85% |
| 2024-12-31 | $289.00K | -72.16% |
| 2023-12-31 | $1.04 Million | -- |
About Polaryx Therapeutics, Inc. Common Stock
Polaryx Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of disease-modifying therapies for rare and pediatric lysosomal storage disorders in the United States. Its pipeline includes PLX-100, a preclinical stage orally administrable combination therapy; PLX-200, a repurposed oral small molecule for the treatment of LSDs; PLX-… Read more